Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)PRNewsWire • 10/02/23
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)PRNewsWire • 09/21/23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in AnnamycinPRNewsWire • 09/18/23
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingPRNewsWire • 09/14/23
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/05/23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming MilestonesPRNewsWire • 08/10/23
Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short SellingPRNewsWire • 08/07/23
Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and WebcastPRNewsWire • 08/03/23
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)PRNewsWire • 07/13/23
Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestPRNewsWire • 06/13/23
Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and WebcastPRNewsWire • 05/04/23
Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)PRNewsWire • 05/02/23
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom FishingZacks Investment Research • 04/24/23
Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer ModelsPRNewsWire • 04/18/23
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/27/23